In a 2-year trial involving patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk, more events of diabetic retinopathy complications occurred in the patients treated with semaglutide injection (3%) compared to placebo (1.8%)
The cerebellar cortex appeared to be the most affected, and the cerebral cortex was the least affected
It is commonly studied in tissue repair, inflammation modulation, and regenerative biology research models
Notes: The compound has not been clinically tested, and any dosing suggestion is purely speculative
Furthermore, BPC 157 alters the expression of specific genes involved in vascular and cellular responses
Animal Toxicology Studies Animal toxicology studies tested doses from 0.0027 mg/lb to 9.1 mg/lb via intraperitoneal, intramuscular, intravenous, and oral routes for up to 6 weeks, finding: No acute toxic or lethal dose No gross or histologic toxicity in major organs No hepatotoxicity or nephrotoxicity Negative Ames test (no mutagenicity) Negative chromosomal aberration tests (no genotoxicity) No teratogenicity in rat pregnancy studies No local injection site irritation The LD1 (minimum lethal dose) could not be achieved despite aggressive testing
